EXPERIMENTAL AND CLINICAL JUSTIFICATION WOUND-HEALING EFFECT OF BIOPLASTIC COLLAGEN MATERIAL IN THE TREATMENT OF CHRONIC WOUNDS

Background. Due to the high prevalence of chronic wounds in patients with diabetes mellitus, the use of effective treatment for them is currently very important. Aim. To substantiate the effectiveness of the bioplastic collagen material "Collost" application in patients with chronic wounds, particularly in those with diabetic foot syndrome. Material and methods. Experimental part: The experiment was performed on 72 male rats using the models of ischemic full-layer skin wound. The experimental groups included group 1 (control, n=36), in which a hydrocolloid dressing was placed in the wound lumen, and group 2 (experimental, n=36) where, after the formation of wounds, 7% Collost gel was injected once intradermally into the wound edges and the wound lumen was filled with the gel. Clinical part: The patients were divided by simple randomization into two groups: group 1 (comparison) included 35 (49.3%) patients who received standard treatment for diabetic foot (surgical treatment, hydrocolloid dressings, orthopedic foot relief, conservative general and diabetic pharmacotherapy); group 2 (main) consisted of 36 (50.7%) patients, whose standard treatment was supplemented with local application of the Collost collagen biomaterial. Results. The use of bioplatic collagen material in patients with chronic wound defects, in particular in diabetic foot syndrome, is experimentally and clinically justified.